Abstract
BI 1569912 is a negative allosteric modulator of NR2B subunit-containing N-methyl-D-aspartate (NMDA) receptors, under development as a treatment for major depressive disorder. Safety, tolerability and food-dependent bioavailability were investigated in a Phase I study conducted at a single site in Germany (Charité, Berlin). Electroencephalography (EEG) and eye-tracking were measured as treatment-response biomarkers to evaluate central target engagement by BI 1569912.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
